TORONTO, ON — May 5, 2026 — Leads & Copy — Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) has successfully closed its previously announced “best efforts” offering. The commercial-stage medical technology company issued 19,533,500 units at a price of $0.35 per unit, raising aggregate gross proceeds of approximately C$6,836,725.
The company expects to issue an additional 1,955,500 units in a final tranche of the Life Offering on or about May 6, 2026, which will bring the total offering up to the maximum offering size of 21,489,000 units (C$7,521,150).
Each unit comprises one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one common share until May 5, 2031, at an exercise price of C$0.50 per common share. Paradigm Capital Inc. acted as lead agent and sole bookrunner, along with Brookline Capital Markets, in connection with the Life Offering.
Perimeter Medical Imaging AI also anticipates completing additional closings of its previously announced concurrent non-brokered private placement of convertible debentures of up to US$3.0 million, for aggregate gross proceeds of up to US$5.0 million. The company expects to raise aggregate proceeds of up to approximately C$14.42 million from the Life Offering together with the Concurrent Debenture Offering.
According to Adrian Mendes, Chief Executive Officer of Perimeter, the Life Offering was led by healthcare-dedicated institutional investors alongside new and existing investors. Mendes said the financing strengthens the company’s balance sheet and positions it to execute the U.S. commercial launch of its FDA PMA-approved, AI-enabled Claire™ device for intraoperative breast cancer margin assessment. The company expects to advance the standard of care by helping reduce breast cancer re-excision rates, while improving patient outcomes.
In connection with the Life Offering, Perimeter paid the agents an aggregate cash commission of approximately C$468,955 and issued 1,339,870 broker warrants, representing 7.0% of the gross proceeds raised and 7.0% of the aggregate number of units issued under the Life Offering, respectively (reduced to 3.5% in respect of sales to certain president’s list purchasers).
The company expects to pay an additional cash commission of approximately C$47,910 and issue an additional 136,885 broker warrants in connection with the closing of the final tranche of the Life Offering. Each broker warrant entitles the agents to acquire one common share at a price of C$0.35 per common share for a period of 24 months following the closing of the Life Offering. The company intends to use the net proceeds of the Life Offering for working capital and general corporate purposes, as described in the offering document.
The Life Offering was made pursuant to the listed issuer financing exemption available under Part 5A of National Instrument 45-106 in each of the provinces and territories of Canada other than Québec. The units were also offered for sale in the United States on a private placement basis pursuant to available exemptions from the registration requirements under the United States Securities Act of 1933, as amended, and applicable state securities laws, and in other offshore jurisdictions provided that no prospectus filing or comparable obligation arose. The securities issued under the Life Offering are not subject to a statutory hold period under applicable Canadian securities laws.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI is a medical technology company focused on transforming cancer surgery with ultra-high-resolution, real-time, advanced imaging tools. The company’s next-generation AI-enabled device, Claire™, was recently approved by the U.S. Food and Drug Administration (FDA). The company’s ticker symbol “PINK” references the pink ribbons used during Breast Cancer Awareness Month.
Indications for Use: The Claire OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with physician interpretation of the images. The Claire OCT System is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.
The Claire OCT System should not be used to replace standard tissue histopathology assessment and should not be used for diagnosis. The device is not intended for use in any of the following individuals: under the age of 18, male, have metastatic cancer (Stage IV), have lobular carcinoma as their primary diagnosis, have had previous ipsilateral breast surgery for benign or malignant disease within two years (including implants and breast augmentation), patients with multi-centric disease (histologically diagnosed cancer in two different quadrants of the breast), unless resected in a single specimen, patients with bilateral disease (diagnosed cancer in both breasts), patients who are currently lactating, patients who are currently pregnant, or concurrent use in surgeries with cryo-assisted localization. Refer to prescriber labeling for full safety information.
Source: Perimeter Medical Imaging AI Inc.
